Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
November 16, 2026


The Baxfendy EU positive opinion came from the European Medicines Agency’s human medicines committee (CHMP) on 12 November 2026. The committee recommended granting a marketing authorisation for Baxfendy, intended for the treatment of insufficiently controlled hypertension. The applicant is AstraZeneca AB. A positive opinion is a recommendation. The European Commission still has to grant the marketing authorisation.
What the Baxfendy EU positive opinion covers
Baxfendy will come as 1 mg and 2 mg film-coated tablets. Its active substance is baxdrostat, which the EMA describes as a selective inhibitor of human aldosterone synthase. The summary explains that aldosterone contributes to hypertension in two ways. It makes the kidneys retain sodium and water, which increases blood volume, and it acts directly on blood vessels, promoting dysfunction, inflammation and fibrosis.
The indication covers adult patients with arterial hypertension that is insufficiently controlled with at least two antihypertensive medicinal products.
What the trials showed
According to the randomised, double-blind, placebo-controlled studies showed reductions in systolic and diastolic blood pressure that are “clinically relevant and statistically significant”. The patients had uncontrolled high blood pressure despite using at least two blood pressure-lowering medicines. The summary does not give effect sizes. Our earlier report on the US decision gives the BaxHTN Phase III figures.
Where this fits
The CHMP meets monthly, and Syenza News has covered the July 2026 batch and the September 2026 batch. The next step is the Commission decision. Our report on Foundayo’s October opinion notes that the Commission normally decides within 67 days.
Source: EMA CHMP summary of opinion, Baxfendy (12 November 2026); EMA medicine page.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.





